Newly launched medical truck brings the emergency room to cardiac arrest patients

University of Minnesota, The Leona M. and Harry B. Helmsley Charitable Trust and health care system partners announce the launch of a truck outfitted with medical equipment and virtual reality technology to help experts attend to patients remotely for extracorporeal membrane oxygenation (ECMO). Part of the Minnesota Mobile Resuscitation Consortium (MMRC), the truck brings the emergency room to cardiac arrest patients and is an innovative step in providing care to cardiac arrest patients who need to be placed on ECMO.

This approach will allow experts to administer treatment on-site in the vehicle — shortening the time to treatment and broadening the area served by MMRC. Every 10-minute delay in treatment for these patients increases the chances of mortality by 15 to 25%. This technology and community partnership aims to save the lives of cardiac arrest patients in scenarios which traditional resuscitation efforts have failed.”


Jason Bartos, President,

Read More

Regional medical staff, 1B patients share their symptoms and emotions after receiving COVID vaccine | Local News

Representatives of Our House Senior Living Assisted Care & Memory Care, Chippewa Falls.

Residents have been waiting a long time for their chance to receive the COVID-19 vaccine and (resident) Pete (Dachel) was the first in line, wide awake and ready to go. He took the lead and we all followed.

A statement from Maggie Smith, MCHES, CPSTI, La Crosse County Health Department health educator and COVID-19 public information officer

Although our department is the lead agency in coordinating vaccine distribution, the majority of our staff were not included in Phase 1A or 1B guidelines from the state.

We continue to adhere to the equitable, ethical allocation coordinated by the Wisconsin Department of Health Services, though we like so many others are eagerly awaiting our turn to receive the vaccine. We ask the community for patience as vaccine rollout continues. The speed of the process is dependent on availability

Read More

Consenting for treatment in advance to reduce leaving the hospital against medical advice among patients with addiction

drug addict
Credit: Pixabay/CC0 Public Domain

Patients with substance use disorders (SUDs) being treated for serious medical conditions are more likely to leave the hospital against medical advice (AMA) than those without addiction. A special type of contract with healthcare providers might enable patients to consent in advance to life-saving medical care—even if they later refuse treatment, according to a commentary in the Journal of Addiction Medicine, the official journal of the American Society of Addiction Medicine (ASAM).

The Substance Use Advance Directive (SUAD) “has the potential to greatly improve the current state of treatment for life-threatening comorbid conditions in SUD patients through reducing AMA discharges,” writes Paul Tobias, MD, JD, MBA, of Ohio Health, Columbus.

But in an accompanying commentary, Kelly K. Dineen, JD, Ph.D., of Creighton University, Omaha, Neb., cites “obvious practical and ethical challenges” to the SUAD concept, including the lack of any legal basis for overruling patients

Read More

Paris Regional Medical Center offering monoclonal antibody treatment for Covid-19 patients | Free

Paris Regional Medical Center announced today that it is offering both bamlanivimab/casirivimab and imdevimab, new monoclonal antibody therapies, for treatment of non-hospitalized patients with a mild or moderate case of Covid-19.

Developed by pharmaceutical companies Eli Lilly/Regeneron Pharmaceuticals Inc., the drug recently received emergency use authorization from the Food and Drug Administration and is now being allocated by the U.S. Department of Health and Human Services in partnership with the Texas Department of State Health Services and other state agencies.

Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful viruses. Bamlanivimab/casirivimab and imdevimab are specifically designed to help block the SARS-CoV-2 virus and prevent the virus from further infecting healthy cells. Administered intravenously, this innovative treatment is designed to help lessen the severity of Covid-19 in individuals who test positive and are at risk for developing a severe form of the disease.

“Paris Regional

Read More